Prognostic Value of Androgen Receptor Expression in Chinese Breast Cancer Cohort

A retrospective analysis of 422 patients with primary ER+/HER2− breast cancer treated at the First Affiliated Hospital of Chongqing Medical University between December 2020 and November 2021. The dataset, authored by Cheng Tian and last updated in May 2026, likely contains clinical and immunohistochemistry data used to evaluate the association between androgen receptor expression and survival outcomes.

Use Cases

• Predict disease-free survival based on androgen receptor expression levels.
• Analyze the relationship between progesterone receptor status and patient outcomes.
• Conduct subgroup analysis on patients receiving neoadjuvant chemotherapy who did not achieve pathological complete response.
• Model the prognostic impact of baseline tumor T stage in ER+/HER2− breast cancer.

Strengths

• 422 patient records from a real-world clinical cohort.
• Focus on a contemporary Chinese population, addressing a gap in Western-centric evidence.
• Analysis includes multivariable Cox models and sensitivity analyses treating AR as a continuous variable.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small at 1.8 MB, potentially limiting statistical power for complex analyses.

Provenance

Source

First Affiliated Hospital of Chongqing Medical University

Collection Method

Retrospective analysis of patient records, with androgen receptor expression assessed by immunohistochemistry.

Time Range

December 2020 to November 2021

Freshness

Last updated 2026-05-11 04:20:55; freshness should be verified.

Geography

China